Citations

Clear

1422 citation(s) found for "White, JB".

1350: NEUROSCIENCE INTENSIVE CARE UNIT READMISSION RISK: ARE MEDICAL PREDICTION MODELS ACCURATE?
Peacock, Sarah , Grek, Ami , Rogers, Emily, White, Launia J. , Naessens, James M. , Freeman, William D.

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 652-652

10.1097/01.ccm.0000645316.26854.71 Get It

1638: READMISSION PREVENTION IN SEPSIS: DEVELOPMENT AND VALIDATION OF A PREDICTION MODEL: REPRESS
Grek, Ami , Rogers, Emily, Peacock, Sarah , Hartjes, Tonja M. , White, Launia J. , Naessens, James M. , Li, Zhuo Ya , Franco, Pablo Moreno

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 794-794

10.1097/01.ccm.0000648456.08467.67 Get It

A Decomposition Method to Assess the Contributions of Geographic and Nongeographic Factors to White-Black Disparities in Health Care
Huckfeldt, Peter J. , Escarce, José J. , Pane, Joseph , Popescu, Ioana

Mayo Clinic

Medical Care | December 17, 2019 | Volume: 58 | Issue: 3 | Pages: e16-e22

10.1097/mlr.0000000000001252 | PMID 32106169 Get It

Background: Black-white gaps in high-quality hospital use are documented, but the relative contributions of various factors are unclear. The objective of this study was to quantify the contributions of differences in geographic and nongeographic factors to the gap, using decomposition methods and data for coronary heart disease. Research Design: We identified white and black fee-for-service beneficiaries aged 65 or older who were hospitalized for acute myocardial infarction (AMI) or coronary artery bypass grafting (CABG) surgery during 2009–2011. We categorized hospitals with AMI mortality rates in the lowest quintile as high-quality hospitals. We first decomposed the white-black gap in high-quality hospital use into a component due to racial differences in region of residence and a within-region component. We then decomposed the within-region differences into contributions due to racial differences in geographic proximity to high-quality hospitals and due to nongeographic factors. Results: The white-black gap in high-quality hospital use was smaller for AMI than for CABG (1.7 percentage points vs. 7.5 percentage points). For AMI, region of residence contributed more to the gap than within-region differences (1.0 percentage point vs. 0.6 percentage points), while for CABG, within-region differences prevailed (2.0 percentage points vs. 5.4 percentage points). For both conditions, the within-region white-black difference in high-quality hospital use was mainly driven by nongeographic factors. Conclusions: Decomposition methods are a useful tool in quantifying the contributions of various factors to the white-black gap in high-quality hospital use and could inform local policy aimed at reducing disparities in hospital quality.
National Quality Forum Guidelines for Evaluating the Scientific Acceptability of Risk-adjusted Clinical Outcome Measures
Maddox, Karen E. Joynt , Nerenz, David R. , Cella, David , Kunisch, Joseph, Walters, Ronald S., White, Susan , Lin, Zhenqiu , Glance, Laurent G. , Johnson, Karen , Borah, Bijan J. , Kurlansky, Paul A. , Perloff, Jennifer N. , Stoto, ­Michael A.

Mayo Clinic

Annals of Surgery | December 17, 2019 | Volume: 271 | Issue: 6 | Pages: 1048-1055

10.1097/sla.0000000000003592 | PMID 31850998 Get It

Quality measurement is at the heart of efforts to achieve high-quality surgical and medical care at a lower cost. Without accurate quality measures, it is not possible to appropriately align incentives with quality. The aim of these National Quality Forum (NQF) guidelines is to provide measure developers and other stakeholders with guidance on the standards used by the NQF to evaluate the scientific acceptability of performance measures. Using a methodologically rigorous and transparent process for evaluating health care quality measures is the best insurance that alternative payment plans will truly reward and promote higher quality care. Performance measures need to be credible in order for physicians and hospitals to willingly partner with payers in efforts to improve population outcomes. Our goal in creating this position paper is to promote the transparency of NQF evaluations, improve the quality of performance measurements, and engage surgeons and all other stakeholders to work together to advance the science of performance measurement.
Competency‐Based Assessment Tool for Pediatric Tracheotomy: International Modified Delphi Consensus
Propst, Evan J. , Wolter, Nikolaus E. , Ishman, Stacey L. , Balakrishnan, Karthik , Deonarain, Ashley R. , Mehta, Deepak, Zalzal, George H., Pransky, Seth M. , Roy, Soham , Myer, Charles M. , Torre, Michele , Johnson, Romaine F. , Lüdemann, Jeffrey P. , Derkay, Craig S. , Hong, Paul , Molter, David, Prager, Jeremy D. , Nguyen, Lily H. P. , Rutter, Michael J. , Zur, Karen B. , Sidell, Douglas R. , Johnson, Liane B. , Cotton, Robin T., Willging, J. Paul, Zdanski, Carlton J. , Manoukian, John J. , Lam, Derek J. , Gantwerker, Eric A. , Husein, Murad , Inglis, Andrew F., Green, Glenn E. , Javia, Luv, Schraff, Scott A. , Soma, Marlene , Deutsch, Ellen S. , Sobol, Steven E., Ida, Jonathan B., Choi, Sukgi S. , Uwiera, Trina C., Shah, Udayan K. , White, David R. , Wootten, Christopher T. , El‐Hakim, Hamdy , Bromwich, Matthew, Richter, Gresham T. , Vijayasekaran, Shyan , Smith, Marshall E. , Vaccani, Jean‐Philippe , Hartnick, Christopher J. , Faucett, Erynne A. , Sidell, Douglas R. , Hong, Paul , Prager, Jeremy D , Nguyen, Lily H P , Zur, Karen , Sidell, Douglas R , Hart, Catherine K , Gantwerker, Eric A , Husein, Murad , Choi, Sukgi , Hartnick, Christopher J , Faucett, Erynne A , Johnson, Romaine F , Sidell, Douglas R , Ishman, Stacey L , Lam, Derek J , Balakrishnan, Karthik , Chun, Robert H. , Hart, Catherine K. , Bauman, Nancy M.

Mayo Clinic

The Laryngoscope | December 10, 2019 | Volume: 130 | Issue: 11 | Pages: 2700-2707

10.1002/lary.28461 | PMID 31821571 Get It

Objectives/HypothesisCreate a competency‐based assessment tool for pediatric tracheotomy.Study DesignBlinded, modified, Delphi consensus process.MethodsUsing the REDCap database, a list of 31 potential items was circulated to 65 expert surgeons who perform pediatric tracheotomy. In the first round, items were rated as “keep” or “remove,” and comments were incorporated. In the second round, experts were asked to rate the importance of each item on a seven‐point Likert scale. Consensus criteria were determined a priori with a goal of 7 to 25 final items.ResultsThe first round achieved a response rate of 39/65 (60.0%), and returned questionnaires were 99.5% complete. All items were rated as “keep,” and 137 comments were incorporated. In the second round, 30 task‐specific and seven previously validated global rating items were distributed, and the response rate was 44/65 (67.7%), with returned questionnaires being 99.3% complete. Of the Task‐Specific Items, 13 reached consensus, 10 were near consensus, and 7 did not achieve consensus. For the 7 previously validated global rating items, 5 reached consensus and two were near consensus.ConclusionsIt is feasible to reach consensus on the important steps involved in pediatric tracheotomy using a modified Delphi consensus process. These items can now be considered to create a competency‐based assessment tool for pediatric tracheotomy. Such a tool will hopefully allow trainees to focus on the important aspects of this procedure and help teaching programs standardize how they evaluate trainees during this procedure.Level of Evidence5 Laryngoscope, 130:2700–2707, 2020
Vacuum-Assisted Subcision for Gluteal Contouring
Carr, Emily, Hoss, Elika, Kollipara, Ramya, Fabi, Sabrina G.

Mayo Clinic

Dermatologic Surgery | December 6, 2019 | Volume: 47 | Issue: 2 | Pages: 294-296

10.1097/dss.0000000000002274 | PMID 31809352 Get It

Anti–PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma
Ene, Chibawanye , Kreuser, Shannon , Jung, M. Katherine , Zhang, Huajia , Moyes, Kara White, Szulzewsky, Frank , Barber, Jason , Cimino, Patrick J. , Wirsching, Hans‐Georg , Patel, Anoop P. , Kong, Paul , Woodiwiss, Timothy , Durfy, Sharon , Houghton, A. McGarry, Crane, Courtney A., Jung, Miyeon, Cimino, Patrick J , Jung, Miyeon, Arora, Sonali , Pierce, Robert Hamilton , Parney, Ian F. , Holland, Eric C.

Mayo Clinic

Neuro-Oncology | December 2, 2019 | Volume: 22 | Issue: 5 | Pages: 639-651

10.1093/neuonc/noz226 | PMID 31793634 Get It

Abstract Background Most glioblastomas recur near prior radiation treatment sites. Future clinical success will require achieving and optimizing an “abscopal effect,” whereby unirradiated neoplastic cells outside treatment sites are recognized and attacked by the immune system. Radiation combined with anti–programmed cell death ligand 1 (PD-L1) demonstrated modest efficacy in phase II human glioblastoma clinical trials, but the mechanism and relevance of the abscopal effect during this response remain unknown. Methods We modified an immune-competent, genetically driven mouse glioma model (forced platelet derived growth factor [PDGF] expression + phosphatase and tensin homolog loss) where a portion of the tumor burden is irradiated (PDGF) and another unirradiated luciferase-expressing tumor (PDGF + luciferase) is used as a readout of the abscopal effect following systemic anti–PD-L1 immunotherapy. We assessed relevance of tumor neoepitope during the abscopal response by inducing expression of epidermal growth factor receptor variant III (EGFRvIII) (PDGF + EGFRvIII). Statistical tests were two-sided. Results Following radiation of one lesion, anti–PD-L1 immunotherapy enhanced the abscopal response to the unirradiated lesion. In PDGF-driven gliomas without tumor neoepitope (PDGF + luciferase, n = 8), the abscopal response occurred via anti–PD-L1 driven, extracellular signal-regulated kinase–mediated, bone marrow–derived macrophage phagocytosis of adjacent unirradiated tumor cells, with modest survival implications (median survival 41 days vs radiation alone 37.5 days, P = 0.03). In PDGF-driven gliomas with tumor neoepitope (PDGF + EGFRvIII, n = 8), anti–PD-L1 enhanced abscopal response was associated with macrophage and T-cell infiltration and increased survival benefit (median survival 36 days vs radiation alone 28 days, P = 0.001). Conclusion Our results indicate that anti–PD-L1 immunotherapy enhances a radiation- induced abscopal response via canonical T-cell activation and direct macrophage activation in glioblastoma.
Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma
Randall, Elizabeth C., Lopez, Begoña G.C., Peng, Sen, Regan, Michael S. , Basu, Sankha S. , Santagata, Sandro , Yoon, Haejin , Haigis, Marcia C. , Agar, Jeffrey N. , Tran, Nhan L. , Elmquist, William F. , Agar, Nathalie Y.R. , Basu, Sankha S , Santagata, Sandro , Agar, Nathalie Y R , Regan, Michael S , Tran, Nhan L , Lopez, Begoña G.C., Abdelmoula, Walid M. , White, Forest M. , Sarkaria, Jann N.

Mayo Clinic

Cancer Research | November 25, 2019 | Volume: 80 | Issue: 6 | Pages: 1258-1267

10.1158/0008-5472.can-19-0638 | PMID 31767628 Get It

Abstract Glioblastoma (GBM) is increasingly recognized as a disease involving dysfunctional cellular metabolism. GBMs are known to be complex heterogeneous systems containing multiple distinct cell populations and are supported by an aberrant network of blood vessels. A better understanding of GBM metabolism, its variation with respect to the tumor microenvironment, and resulting regional changes in chemical composition is required. This may shed light on the observed heterogeneous drug distribution, which cannot be fully described by limited or uneven disruption of the blood–brain barrier. In this work, we used mass spectrometry imaging (MSI) to map metabolites and lipids in patient-derived xenograft models of GBM. A data analysis workflow revealed that distinctive spectral signatures were detected from different regions of the intracranial tumor model. A series of long-chain acylcarnitines were identified and detected with increased intensity at the tumor edge. A 3D MSI dataset demonstrated that these molecules were observed throughout the entire tumor/normal interface and were not confined to a single plane. mRNA sequencing demonstrated that hallmark genes related to fatty acid metabolism were highly expressed in samples with higher acylcarnitine content. These data suggest that cells in the core and the edge of the tumor undergo different fatty acid metabolism, resulting in different chemical environments within the tumor. This may influence drug distribution through changes in tissue drug affinity or transport and constitute an important consideration for therapeutic strategies in the treatment of GBM. Significance: GBM tumors exhibit a metabolic gradient that should be taken into consideration when designing therapeutic strategies for treatment. See related commentary by Tan and Weljie, p. 1231
Diet Mimicking “Fast Food” Causes Structural Changes to the Retina Relevant to Age-Related Macular Degeneration
Roddy, Gavin W. , Rosa, Robert H. , Viker, Kimberly, Holman, Bradley H., Hann, Cheryl R., Krishnan, Anuradha , Bakri, Sophie J. , Fautsch, Michael P. , Viker, Kimberly B, Gores, Gregory J.

Mayo Clinic

Current Eye Research | November 18, 2019 | Volume: 45 | Issue: 6 | Pages: 726-732

10.1080/02713683.2019.1694156 | PMID 31735070 Get It

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, Kristin Alyse, Hwang, Amie E. , Sheng, Xin , Hom, Victor, Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , John, Esther M. , Stroup, Antoinette M. , Zangari, Maurizio , Carpten, John D. , Mehta, Jayesh, Colditz, Graham A. , Wolf, Jeffrey, Martin, Thomas G. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence, Auclair, Daniel , Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Conti, David V. , Haiman, Christopher A. , Witte, John S. , John, Esther M , Colditz, Graham A , Conti, David V , Kachuri, Linda , Rand, Kristin A. , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Bernstein, Leslie , Rhee, Frits van , Olshan, Andrew F. , Zheng, Wei , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Wolf, Jeffrey L. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Chiu, Brian C.‐H. , Stram, Daniel O. , Morgan, Gareth J. , Lonial, Sagar , Orlowski, Robert Z. , Ziv, Elad , Cozen, Wendy

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 4379-4379

10.1182/blood-2019-129298 Get It

Multiple myeloma (MM) is a neoplasm thought to arise from a damaged germinal center B-cell that progresses to a plasma cell clone arising in bone marrow. MM comprises 20% of all hematologic cancer deaths. Persons of African ancestry (AA) have a 1.5 to 2-fold higher risk compared to individuals of European ancestry (EA). Genetically driven differences in hematopoiesis may lead to variation in the levels white blood cell (WBC) subsets which could, in turn, be associated with MM etiology. There are differences in genetic determinants of WBC traits between EA and AA populations, with possible implications for the racial disparity in risk. We tested the above hypothesis using Mendelian randomization (MR), an approach that leverages genetic determinants of specific traits (i.e. WBC counts) to estimate their effects on the risk of an outcome; and a transcriptome-wide association study (TWAS), which utilizes genetic predictors of gene expression to identify susceptibility genes. These analytic approaches were applied to data from the African American Multiple Myeloma Study (AAMMS) consisting of 1813 cases and 8871 AA cancer-free controls to examine how differences in heritable WBC gene expression profiles influence MM risk. Genetic determinants of variation in WBC subsets in AA were obtained from the literature and supplemented with new genome-wide association findings in AA subjects from the UK Biobank cohort (n=6108). Odds ratios (OR) for MM per 1 standard deviation (SD) increase in each WBC phenotype were estimated using independent (linkage disequilibrium (LD) r2<0.10) variants with P<10-6 as genetic instruments. Analyses based on variants associated with WBC traits in AA populations did not identify any statistically-significant associations between MM risk and WBC overall (p=0.81, using 15 SNPs) or subsets (lymphocytes, monocytes, eosinophils, neutrophils and basophils, p>0.05 for each). However, when we applied genetic determinants of WBC identified in 330,000 cancer-free EA UK Biobank participants (P<10-8, replication P<0.05, LD r2<0.05), a statistically significant inverse relationship emerged between increasing lymphocyte counts and MM risk (OR=0.80, 95% CI: 0.66-0.97, p=0.02, using 385 SNPs), as well as increasing basophil counts (OR=0.63, 95% CI: 0.41-0.96, p=0.03, using 140 SNPs). Next, we examined the association between WBC gene expression profiles and MM risk in AAMMS data. We applied published and validated ancestry-specific models developed using the PrediXcan approach, which leverage germline genetic and transcriptomic data from the Multi-Ethnic Study of Atherosclerosis (MESA) (Mogil et al. PMID: 30096133). The primary TWAS used gene expression models trained in AA subjects (n=233), with sensitivity analyses using models developed in AA and Hispanic subjects (n=585). The TWAS significance threshold was based on the number of genes with significant germline prediction models (p<0.05 and R2 ≥0.05) in AA, corresponding to P < 0.05/2700 = 1.85×10-5. The expression of two genes was significantly associated with MM risk: KANK1at 9p24.3 (P = 1.01×10-5) and DNAJC27at 2p23.3 (P = 1.56×10-5). KANK1is a candidate tumor suppressor gene for renal cell carcinoma and has recently been associated with MM risk in AA [Du, Blood 2017 130:3058]. Here we provide additional evidence for its role in MM etiology via gene expression-mediated mechanisms. DNAJC27 (previously known as RBJ) is a novel MM risk gene linked to constitutive activation of ERK in solid tumors. We also identified two suggestively associated genes: PRR14 (P = 1.34×10-4; combined AA-Hispanic sample: P = 1.56×10-6), which has been linked to MM risk in EA populations, and PARP16 (P = 9.46×10-5). To our knowledge this is the first study to comprehensively examine variation in WBC traits and gene expression profiles with respect to MM risk in AA. Our TWAS analysis leveraged data from the largest collection of genetic and gene expression data in AA, enabling ancestry-matched inference and identification of two novel risk genes. Although the limited availability of genetic instruments for WBC limited the power of MR analysis, findings using variants identified in European populations may offer some insight into trans-ethnic etiologic pathways and contribute to risk stratification strategies using genetic and blood cell count biomarkers. Future studies, particularly with MGUS-free controls, are needed to validate these results. Disclosures Song: Millennium Pharmaceuticals Inc: Employment. Rand:Ancestry.com: Employment. Ailawadhi:Cellectar: Research Funding; Janssen: Consultancy, Research Funding; Celgene: Consultancy; Pharmacyclics: Research Funding; Amgen: Consultancy, Research Funding; Takeda: Consultancy. Nooka:Takeda: Honoraria, Other: advisory board participation; Janssen: Honoraria, Other: advisory board participation; GSK: Honoraria, Other: advisory board participation; Spectrum pharmaceuticals: Honoraria, Other: advisory board participation; Adaptive technologies: Honoraria, Other: advisory board participation; Amgen: Honoraria, Other: advisory board participation; Celgene: Honoraria, Other: advisory board participation; BMS: Honoraria, Other: advisory board participation. Singhal:Bureau of Millennium/Takeda, Celgene, Janssen, Celgene, Bristol-Myers Squibb and Bluebird: Speakers Bureau. van Rhee:Takeda: Consultancy; Sanofi Genzyme: Consultancy; Castleman Disease Collaborative Network: Consultancy; EUSA: Consultancy; Adicet Bio: Consultancy; Kite Pharma: Consultancy; Karyopharm Therapeutics: Consultancy. Mehta:Millennium/Takeda, Celgene; stock in Celgene, Bristol-Myers Squibb and Bluebird: Speakers Bureau. Wolf:Takeda: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Janssen: Consultancy; Amgen: Consultancy. Martin:Roche and Juno: Consultancy; Amgen, Sanofi, Seattle Genetics: Research Funding. Fiala:Incyte: Research Funding. Terebelo:Jannsen: Speakers Bureau; Celgene: Honoraria; Newland Medical Asociates: Employment. Anderson:Bristol-Myers Squibb: Other: Scientific Founder; Oncopep: Other: Scientific Founder; Amgen: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Sanofi-Aventis: Other: Advisory Board. Vij:Bristol-Myers Squibb: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Genentech: Honoraria; Janssen: Honoraria; Karyopharm: Honoraria; Sanofi: Honoraria; Takeda: Honoraria, Research Funding. Bernal-Mizrachi:TAKEDA: Research Funding; Kodikas Therapeutic Solutions, Inc: Equity Ownership; Winship Cancer Institute: Employment, Patents & Royalties. Morgan:Amgen, Roche, Abbvie, Takeda, Celgene, Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Other: research grant, Research Funding. Zonder:Celgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Intellia: Consultancy, Membership on an entity's Board of Directors or advisory committees; Caelum: Consultancy, Membership on an entity's Board of Directors or advisory committees; Alnylam: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees. Huff:Member of Safety Monitoring Board for Johnson and Johnson: Membership on an entity's Board of Directors or advisory committees; Karyopharm, Sanofi, MiDiagnostics: Consultancy. Lonial:Karyopharm: Consultancy; Takeda: Consultancy, Research Funding; Amgen: Consultancy; BMS: Consultancy; Janssen: Consultancy, Research Funding; GSK: Consultancy; Celgene Corporation: Consultancy, Research Funding; Genentech: Consultancy. Orlowski:Poseida Therapeutics, Inc.: Research Funding.